 - Patient has failed discontinued for progression or toxicity one prior line of chemotherapy for metastatic disease, preferably oxaliplatin-based e.g. FOLFOX, CAPOX. Note that substitutions of oral versus IV 5-FU formulations, changes in 5-FU schedules, or discontinuationsre-starting of the same chemotherapy drugs will not be considered as separate lines of therapy, nor will the addition of biologics such as bevacizumab, cetuximab, or panitumumab 